Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of BMS-986166 and branebrutinib in moderate to severe atopic dermatitis
2020-004767-77Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of udifitimod and branebrutinib in atopic dermatitis (AD) (5 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 16. Started Aug 2021; status: active.
02
Drugs
udifitimodbranebrutinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-004767-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004767-77.